Abstract: The present invention identifies further to AKR1C1 also AKR1C2 as a lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C genes, in particular of the AKR1C2 gene, or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.

Abstract: A composition includes ?-cyclodextrin and hydroxytyrosol and/or their nutraceutically acceptable derivatives, such as salts or esters, in particular for application as a food supplement or medical device, in alternative as a cosmetic mouthwash or traditional medicinal product of plant origin (botanical) or food for special medical purposes. The composition is effective in preventing SARS-CoV-2 infection. The composition is suitable for an application as a spray or mouthwash. A related dispensing device is also described. The composition is also effective in contrasting halitosis in subjects that wear a mask for a prolonged period.

Abstract: A composition, in particular in gel form, includes Lactobacillaceae reuteri to be used in the prevention and/or treatment of oral mucositis, particularly radio-induced oral mucositis. In its gel form, the composition also includes: a polyoxy-alkylene copolymer, in particular a polyoxy-ethylene-propylene copolymer, preferably with the general formula HO[CH2CH2O]x[CH2CH(CH3)O]y[CH2CH2O]zH, where preferably x=99, y=67, and z=99; a mucoadhesive polymer, preferably cellulosic in nature, in particular carboxymethyl cellulose; and one or more stabilizers, preferably chosen from sugars such as sucrose, trehalose, mannitol, sorbitol and glucose, sodium ascorbate, very preferably the sugar is sucrose. Treatments of other mucositis with the composition, such as intestinal leakage, are conceivable. A procedure to produce the composition in gel and lyophilized form is described.

Abstract: The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.